Propanc Biopharma Files 8-K on Agreements and Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $33,750, $30,375, $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, equity-sale
TL;DR
Propanc Biopharma just filed an 8-K detailing new debt and equity sales.
AI Summary
Propanc Biopharma, Inc. entered into a material definitive agreement on June 26, 2024, related to a direct financial obligation. The company also reported on unregistered sales of equity securities. The filing includes financial statements and exhibits.
Why It Matters
This filing indicates new financial obligations and equity transactions for Propanc Biopharma, which could impact its financial structure and shareholder equity.
Risk Assessment
Risk Level: medium — The filing mentions material definitive agreements and unregistered sales of equity, which can introduce financial risks and dilution.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- June 26, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Propanc Biopharma enter into?
The filing states Propanc Biopharma, Inc. entered into a material definitive agreement on June 26, 2024, which also constitutes the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 26, 2024.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the entry into a material definitive agreement, the creation of a direct financial obligation, unregistered sales of equity securities, and includes financial statements and exhibits.
Where is Propanc Biopharma, Inc. incorporated?
Propanc Biopharma, Inc. is incorporated in Delaware.
What is the business address of Propanc Biopharma, Inc. as listed in the filing?
The business address listed is 302, 6 Butler Street, Camberwell, VIC, 3124, Australia.
Filing Stats: 1,074 words · 4 min read · ~4 pages · Grade level 12.6 · Accepted 2024-07-02 13:29:54
Key Financial Figures
- $33,750 — ny in the aggregate principal amount of $33,750 (the "Note"), for a purchase price of $
- $30,375 — 0 (the "Note"), for a purchase price of $30,375. The Company intends to use the net pro
- $0.001 — common stock of the Company, par value $0.001 per share (the "Common Stock"), at the
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex4-1.htm (EX-4.1) — 135KB
- ex10-1.htm (EX-10.1) — 146KB
- 0001493152-24-025929.txt ( ) — 560KB
- ppcb-20240626.xsd (EX-101.SCH) — 3KB
- ppcb-20240626_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240626_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 1, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer